RT Journal Article
SR Electronic
T1 Post–COVID-19 multisystem inflammatory syndrome in children
JF Canadian Family Physician
JO Can Fam Physician
FD The College of Family Physicians of Canada
SP 594
OP 596
DO 10.46747/cfp.6708594
VO 67
IS 8
A1 Michelle M. Kim
A1 Srinivas Murthy
A1 Ran D. Goldman
YR 2021
UL http://www.cfp.ca/content/67/8/594.abstract
AB Question The effect of acute coronavirus disease 2019 (COVID-19) on morbidity and mortality in children has been relatively small. If a child presents to my office with persistent fever and systemic hyperinflammation but no known exposure to COVID-19, how likely are they to have multisystem inflammatory syndrome in children (MIS-C)? What is currently known about MIS-C and what is the prognosis for children affected by it?Answer Amid the COVID-19 pandemic, the emergence of a novel condition presents yet another challenge to clinicians, public health professionals, and the pediatric population. Multisystem inflammatory syndrome in children is a rare but potentially severe condition seen in children with evidence of COVID-19 approximately 2 to 6 weeks before symptom onset. Common signs and symptoms include persistent fever, systemic hyperinflammation, gastrointestinal symptoms (eg, abdominal pain, vomiting, diarrhea), mucocutaneous changes (eg, rash, conjunctivitis), headache, or cardiac dysfunction. As many children present as asymptomatic or with mild symptoms of COVID-19, the development of MIS-C can seem sudden and surprising to families and providers. Although children with MIS-C usually require hospitalization, the outcomes are largely favourable with prompt recognition and intense therapy.